Lupus & antiphospholipid syndrome
Development of a novel meta-polygenic risk score for risk assessment and clinical manifestation prediction in systemic lupus erythematosus
Authors' conclusion
We developed the first metaPRS of SLE by integrating genetic characteristics from multiple SLE-related risk factors, offering a new perspective for risk stratification and early diagnosis.
Study context
- Population
- East Asian population; Systemic lupus erythematosus (SLE) patients and controls from the authors' own cohort
- Participants
- 2,388 vs 1,132
- Comparison
- Meta-polygenic risk score (metaPRS) vs conventional PRS based solely on SLE risk genetic variants
- Patientsn = 2,388
- Controlsn = 1,132reference
- Outcome
- Prediction of SLE by metaPRS
Methodological detailspolygenic risk score, elastic net regression, internal validation via bootstrapping
- Polygenic risk score
- Elastic net regression
- Internal validation via bootstrapping
Main finding
As reported in the abstract
- metaPRS OR
- 2.12
- metaPRS AUC
- 0.69
- Risk stratification, high risk vs low risk, OR
- 4.93 (p<2e-16)
- metaPRS vs conventional PRS: increase in OR
- 4.43%
- metaPRS vs conventional PRS: improvement in AUC
- p=0.046
Observational data: associations, not effects.
Further findings
Trait-level polygenic risk scores (PRSs) significantly associated with SLE
- Five trait-level PRSs: SLE development, smoking initiation, serum selenium levels, endometriosis and Graves' disease
- 5
Clinical manifestations
- metaPRS associated with positivity for multiple autoantibodies
- Better performance in childhood-onset vs adult-onset SLE
- Both PRSSLE and PRSriskfactor contributed to SLE susceptibility; clinical manifestations exclusively driven by PRSSLE
Original publication
Development of a novel meta-polygenic risk score for risk assessment and clinical manifestation prediction in systemic lupus erythematosus. RMD Open. Published 25 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →